Evaluación de Fenómenos Hidráulicos y modelamiento Bidimensional con HEC-RAS en el Canal Chanquin - Valle de Virú, del segundo al séptimo tramo

La presente investigación se desarrolló entre el segundo y el séptimo tramo del canal Canal Integrador de la Margen Derecha (Toma del canal Chanquín), ubicada en la parte media y baja del Valle de Virú, Distrito Virú, Provincia de Virú, Departamento de la Libertad . Tiene como objetivos evaluar los Fenómenos Hidráulicos del Canal “Chanquin” del Valle de Virú y desarrollar el modelamiento Bidimensional con HEC-RAS del segundo al séptimo tramo. La Evaluación de Fenómenos Hidráulicos se desarrolló mediante inspección técnica, para posteriormente realizar un modelamiento Bidimensional con HEC-RAS. Por el cual logramos obtener las condiciones en las cuales se encuentra la toma lateral del canal Chanquin, además se desarrolló el modelado de cada uno de los tramos en estudio, mediante el cual se logró determinar las ubicaciones exactas de los tramos en los que se presentan problemas de desborde. Los resultados demuestran problemas encontrados en el expediente técnico, primero es el alineamiento realizado al momento de diseñar el canal, es decir, el alineamiento se ha encontrado desfasado respecto al cauce natural; por ende, la propuesta del trazo final no fue la más favorable. Podemos decir que las anomalías existentes en dichos tramos del canal; como turbulencia excesiva y desbordamientos se debe al mal trazado del alineamiento; y que por no respetarse las curvas naturales del cauce, el flujo no sea capaz de perder energía ya que se sabe que las curvas ayudan a disipar la energía cinética y ayuda a contrarrestar desbordamientos de agua en los terrenos; es por eso que, entre el tramo de estudio se encontró que las curvas existentes no generan influencia notoria en la transitabilidad del flujo. Para finalizar se plantean alternativas de mejora basándose en el análisis realizado y los resultados obtenidos, todo esto con la finalidad de mitigar los problemas ocasionados por el desbordamiento del canal en estudio.The present investigation was developed between the second and seventh sections of the Right Bank Integrating Canal (Chanquin Canal Intake), located in the middle and lower part of the Viru Valley, Viru District, Viru Province, Department of La Libertad. Its objectives are to evaluate the hydraulic phenomena of the “Chanquin” canal of the Viru Valley and to develop the two-dimensional modeling with HEC-RAS from the second to the seventh section. The Evaluation of Hydraulic Phenomena was developed through technical inspection, to later carry out a Bidimensional modeling with HEC-RAS. By which we were able to obtain the conditions in which the lateral intake of the Chanquin canal is located. In addition, the modeling of each of the sections under study was developed, by which we were able to determine the exact locations of the sections in which overflow problems occur. The results show problems found in the technical file, first, the alignment made at the time of designing the canal, i.e., the alignment has been found to be out of phase with respect to the natural channel; therefore, the final layout proposal was not the most favorable. We can say that the anomalies existing in these sections of the canal, such as excessive turbulence and overflows, are due to the poor alignment; and that by not respecting the natural curves of the channel, the flow is not able to lose energy, since it is known that the curves help dissipate kinetic energy and help counteract water overflows on the land; that is why, in the study section, it was found that the existing curves do not have a noticeable influence on the flow's trafficability. Translated with DeepL.com (free version) Finally, improvement alternatives are proposed based on the analysis carried out and the results obtained, all with the purpose of mitigating the problems caused by the overflow of the canal under studyTesi

Using [Ne V]/[Ne III] to Understand the Nature of Extreme-Ionization Galaxies

Spectroscopic studies of extreme-ionization galaxies (EIGs) are critical to our understanding of exotic systems throughout cosmic time. These EIGs exhibit spectral features requiring >54.42 eV photons: the energy needed to fully ionize helium into He2+ and emit He II recombination lines. They are likely key contributors to reionization, and they can also probe exotic stellar populations or accretion onto massive black holes. To facilitate the use of EIGs as probes of high ionization, we focus on ratios constructed from strong rest-frame UV/optical emission lines, specifically [O III] 5008, H-beta, [Ne III] 3870, [O II] 3727,3729, and [Ne V] 3427. These lines probe the relative intensity at energies of 35.12, 13.62, 40.96, 13.62 eV, and 97.12, respectively, covering a wider range of ionization than traced by other common rest-frame UV/optical techniques. We use ratios of these lines ([Ne V]/[Ne III] = Ne53 and [Ne III]/[O II]), which are closely separated in wavelength, and mitigates effects of dust attenuation and uncertainties in flux calibration. We make predictions from photoionization models constructed from Cloudy that use a broad range of stellar populations and black hole accretion models to explore the sensitivity of these line ratios to changes in the ionizing spectrum. We compare our models to observations from the Hubble Space Telescope and James Webb Space Telescope of galaxies with strong high-ionization emission lines at z ~ 0, z ~ 2, and z ~ 7. We show that the Ne53 ratio can separate galaxies with ionization from 'normal' stellar populations from those with AGN and even 'exotic' Population III models. We introduce new selection methods to identify galaxies with photoionization driven by Population III stars or intermediate-mass black hole accretion disks that could be identified in upcoming high-redshift spectroscopic surveys.Comment: 16 pages, 5 figures, 1 table. Accepted in Ap

Optimization in computational systems biology

Optimization aims to make a system or design as effective or functional as possible. Mathematical optimization methods are widely used in engineering, economics and science. This commentary is focused on applications of mathematical optimization in computational systems biology. Examples are given where optimization methods are used for topics ranging from model building and optimal experimental design to metabolic engineering and synthetic biology. Finally, several perspectives for future research are outlined

Envenomations by Bothrops and Crotalus Snakes Induce the Release of Mitochondrial Alarmins

Skeletal muscle necrosis is a common manifestation of viperid snakebite envenomations. Venoms from snakes of the genus Bothrops, such as that of B. asper, induce muscle tissue damage at the site of venom injection, provoking severe local pathology which often results in permanent sequelae. In contrast, the venom of the South American rattlesnake Crotalus durissus terrificus, induces a clinical picture of systemic myotoxicity, i.e., rhabdomyolysis, together with neurotoxicity. It is known that molecules released from damaged muscle might act as ‘danger’ signals. These are known as ‘alarmins’, and contribute to the inflammatory reaction by activating the innate immune system. Here we show that the venoms of B. asper and C. d. terrificus release the mitochondrial markers mtDNA (from the matrix) and cytochrome c (Cyt c) from the intermembrane space, from ex vivo mouse tibialis anterior muscles. Cyt c was released to a similar extent by the two venoms whereas B. asper venom induced the release of higher amounts of mtDNA, thus reflecting hitherto some differences in their pathological action on muscle mitochondria. At variance, injection of these venoms in mice resulted in a different time-course of mtDNA release, with B. asper venom inducing an early onset increment in plasma levels and C. d. terrificus venom provoking a delayed release. We suggest that the release of mitochondrial ‘alarmins’ might contribute to the local and systemic inflammatory events characteristic of snakebite envenomations

Micromechanical Properties of Injection-Molded Starch–Wood Particle Composites

The micromechanical properties of injection molded starch–wood particle composites were investigated as a function of particle content and humidity conditions. The composite materials were characterized by scanning electron microscopy and X-ray diffraction methods. The microhardness of the composites was shown to increase notably with the concentration of the wood particles. In addition,creep behavior under the indenter and temperature dependence were evaluated in terms of the independent contribution of the starch matrix and the wood microparticles to the hardness value. The influence of drying time on the density and weight uptake of the injection-molded composites was highlighted. The results revealed the role of the mechanism of water evaporation, showing that the dependence of water uptake and temperature was greater for the starch–wood composites than for the pure starch sample. Experiments performed during the drying process at 70°C indicated that the wood in the starch composites did not prevent water loss from the samples.Peer reviewe

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)